Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism

Sponsor
Chongqing Medical University
Study ID
NCT05924620
Phase
PHASE4
Status
Completed

Conditions

  • Primary Aldosteronism

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • finerenone — DRUG
    Patients with PA divided into Intervention group need to take finerenone for 60 days (20mg qd).

Study Details

To study the efficacy and safety of finerenone in patients with primary aldosteronism

Key Dates

Start date
Jun 21, 2023
Status verified
Jul 2023
Primary completion
Mar 12, 2024
Completion
Mar 12, 2024

Study Design

Enrollment
60 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Patients with PA using finerenone
    Patients with PA divided into this group need to take finerenone for 60 days (20mg qd)
  • No Intervention: Patients with PA using spironolactone
    Patients with PA divided into this group need to take spironolactone for 60 days (20mg qd)

Primary Outcome Measure

Compare the change of daytime mean systolic blood pressure in the overall cohort between two groups. [ Time Frame: At baseline and 2 month of follow-up ]

Related Studies